NO inhalation
PreclinicalSmall molecule
NO inhalation is one of 54 small molecule programs targeting Pulmonary Hypertension. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1COVID-19 Vaccine
ModernaPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Selenium
SSWOG Cancer Research Network
Preclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Tpa
UUniversity of Florida
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NO inhalation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanghai Zhongshan Hospital